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Abstract
Alternative splicing is a regulated process that results in expression of specific mRNA and
protein isoforms. Alternative splicing factors determine the relative abundance of each iso-
form. Here we focus on MBNL1, a splicing factor misregulated in the disease myotonic dys-
trophy. By altering the concentration of MBNL1 in cells across a broad dynamic range, we
show that different splicing events require different amounts of MBNL1 for half-maximal
response, and respond more or less steeply to MBNL1. Motifs around MBNL1 exon 5 were
studied to assess how cis-elements mediate the MBNL1 dose-dependent splicing
response. A framework was developed to estimate MBNL concentration using splicing
responses alone, validated in the cell-based model, and applied to myotonic dystrophy
patient muscle. Using this framework, we evaluated the ability of individual and combina-
tions of splicing events to predict functional MBNL concentration in human biopsies, as well
as their performance as biomarkers to assay mild, moderate, and severe cases of DM.
Author Summary
Our studies provide insight into the mechanisms of myotonic dystrophy, the most com-
mon adult form of muscular dystrophy. In this disease, a family of RNA binding proteins
is sequestered by toxic RNA, which leads to mis-regulation and disease symptoms. We
have created a cellular model with one of these family members to study how these RNA
binding proteins function in the absence of the toxic RNA. In parallel, we analyzed tran-
scriptomic data from over 50 individuals (44 affected by myotonic dystrophy) with a
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Introduction
Alternative splicing increases the coding potential of a gene and importantly, allows for regula-
tion of expression of specific isoforms in a developmental and tissue-specificmanner. Regula-
tion of alternative splicing is integral for a variety of biological processes including
erythropoiesis, neuronal differentiation, and embryonic stem cell programming [1,2]. Misregu-
lation of alternative splicing alters isoform ratios and can cause cancers, muscular dystrophies,
and neurological diseases [1–5]. Isoform ratios can be altered by differential expression of tis-
sue specific factors [6,7]. Active areas of investigation in the alternative splicing field include
how concentrations of alternative splicing factors affect isoform ratios, and what properties
determine whether an isoform is responsive to a broad range of splicing factor concentrations
or sensitive to a threshold level of activity.
To address these questions, we focused on alternative splicing regulation by MBNL1, an
RNA binding protein involved in muscle, heart, and CNS development [8,9]. In the disease
myotonic dystrophy, the activities of MBNL1 protein and its paralogs,MBNL2 and MBNL3,
are reduced via sequestration to toxic RNAs, resulting in a titration of MBNL proteins away
from their pre-mRNA substrates. MBNL proteins bind to YGCY motifs using Zn finger RNA
binding motifs [10,11], including sequences found in the toxic RNAs (expanded CUG and
CCUG repeats) that cause both myotonic dystrophy type 1 (DM1) and myotonic dystrophy
type 2 (DM2) [12–16]. As has been observed in other microsatellite repeat diseases, the average
length of the repeat in patients is loosely correlated with age of onset; repeat lengths also vary
across cells and tissues within a single patient, potentially sequesteringMBNL proteins to dif-
fering degrees [17]. MBNL splicing targets are differentially affected by the disease; DM1
patient samples exhibit a broad range of alternative exon inclusion levels, as compared to con-
trol samples containing low numbers of repeats [17–19], and MBNL1-dependent splicing
events were shown to behave differently in response to different doses of MBNL1 protein [20].
Tunable systems can be used to control expression of specific genes and they can be used to
produce a range of mRNA and protein isoforms, and phenotypes that change gradually or
sharply, in response to stimuli [21]. Here, we use a tunable system to demonstrate that splicing
events are responsive to MBNL1 dose, and characterize their behavior over a range of MBNL1
protein levels. We found that dose-responsive behaviors differ in their steepness, and differ in
the protein concentration required to reach half-maximal splicing activity. By further studying
a splicing event that is highly conserved between species, we assessed the importance of
MBNL1 cis-element organization in controlling dose-response behavior. Similar to the cell-
based studies, analysis of muscle biopsies from DM1 patients revealed that splicing events are
not perturbeduniformly; here we characterize those splicing events across patients and calcu-
late the inferredMBNL dose, or predicted freeMBNL protein concentration, in each patient.
These studies lead to predictions for which alternative splicing events are the most robust dis-
ease biomarkers.
Results
A cell model with a broad concentration range of MBNL1
A tetracycline-inducible Flp-In T-REx system (Invitrogen) was utilized to express HA-tagged
MBNL1 in HEK293 cells (Fig 1A), to allow precise control of HA-MBNL1 concentrations as a
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function of doxycycline (dox) (0.5 ng/ml to 10 ng/ml). HA-MBNL1 expression covered a
broad range (Fig 1B). Consistent with the low detection of MBNL1 protein in untreated
HEK293 cells, low MBNL1 protein levels have been described in the literature in the kidney
compared to skeletal muscle and heart in human [8,16]. Knock down of MBNL1 and seques-
tration of MBNL1/2/3 proteins or expression of 960 CUG interrupted repeats resulted in only
minimal or modest changes in the percentage of splicing inclusion ΔC for the splicing events
tested (Figs 2 and 3), also consistent with low MBNL protein expression in HEK293 cells and
that MBNL1 is the predominant paralog. Quantification of transcripts fromHEK293 RNA seq
data confirmed that MBNL1 transcripts were expressed at higher levels than MBNL2/3 (S1
Fig). This system allowed us to generate a twenty-fold dynamic range of MBNL1 protein con-
centration and activity in cells.
Expression of MBNL1 was achieved at lower concentrations of doxycycline (dox) than typi-
cally used for tet-on experiments (> 5 ng/ml). A sigmoidal-shapedMBNL1 concentration
curvewas observedwhen steady-state MBNL1 levels were plotted against the log of the dox
concentration (Fig 1C). Maximal MBNL1 protein accumulation was approximately ten-fold
higher than endogenous levels (Fig 1B) and the concentration was reduced two-fold using siR-
NAs to knock down the expression of endogenousMBNL1 to achieve the minimal concentra-
tions (Fig 1B).
A schematic representation of a typical dose-response curve used to study a hypothetical
MBNL1 regulated cassette exon, whereMBNL1 promotes skipping, is shown in Fig 1D. The
percent spliced in value (C) is plotted as a function of the log of the MBNL1 dose. This sche-
matic curvewas fitted to a four-parameter dose-response equation so that parameters that
relate to biological phenomena, i.e. concentration or EC50 and steepness of response, could be
used to describe the dose-response data (Fig 1D). The slope of each curve provides information
about the responsiveness of an event over the applied MBNL1 concentration range while the
EC50 describes the relative amount of protein required for splicing activity.
MBNL1 target exons exhibit dose-dependency, and differ in the amount
of MBNL1 required for regulation
HA-MBNL1 levels were controlled with the dox-inducible system to generate dose-response
curves of sevenMBNL1 regulated cassette exons within genes that are expressed in HEK293
cells (Fig 2). Six of the selected events were previously validated as MBNL regulated exons and
are well characterized in the DM1 field:MBNL1 exon 5,MBNL2 exon 5, ATP2A1 exon 22, FN1
exon 25, INSR exon 10, and NFIX exon 7 [10,22–28].We also studied CLASP1 exon 19, an
exon that was identified to be dysregulated in the DM1 patient data set that is described below.
The CLASP1 event, to our knowledge, has not been describedpreviously. MBNL1 promotes
exon inclusion of the CLASP1 exon in this study likely through binding to YGCYs within the 5'
region of the intron located downstream of the regulated exon; this observation is consistent
with MBNL1 binding adjacent to enhanced exons [10,28,29]. A previous study reported that
Fig 1. Titration of MBNL1 using an inducible tet-on system. (A) HEK293 cells were stably transfected to
integrate a tetracycline inducible HA-MBNL1 expression construct into the genome. Addition of the
tetracycline analog, doxycycline, de-represses inhibition of transcription by binding to the tet Repressor
resulting in expression of full length HA-MBNL1 mRNA. (B) MBNL1 immuno-blot showing MBNL1 protein
gradient resulting from dox (ng/ml) titrations. GAPDH serves as a loading control. The first lane represents
treatment with control siRNA and the second lane represents treatment with a pool of siRNA against MBNL1.
(C) Quantification of the MBNL1 immunoblot (in triplicate) plotted against log[dox]. (D) Schematic showing a
theoretical example of the dose-dependent relationship between log[MBNL1] and percent spliced in (psi,Ψ),
where MBNL1 levels are determined by Western relative to GAPDH. Curve fitting parameters EC50, slope,
Ψmin, andΨmax are illustrated.
doi:10.1371/journal.pgen.1006316.g001
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Fig 2. MBNL1 dose-responses. (A-G) Dose-response curves and splicing gels of individual events (A) MBNL2 (B) MBNL1 (C) ATP2A1 (D) CLASP1
(E) FN1 (F) INSR (G) NFIX. Dox (ng/ml) was titrated to induce MBNL1 expression in HEK293 cells or treated with control siRNA or siRNA against
MBNL1. siRNA treatment is not shown for events with transcripts that would be targeted by knock-down (MBNL1/2). RNA was isolated from the cells,
RT-PCR was performed and DNA products were resolved on a native gel and isoform ratios quantified.Ψ values were plotted against the log
(HA-MBNL1) treatment and fitted to a four-parameter dose-response curve. Splicing assays and western blots for MBNL1 protein quantification were
performed in triplicate. (H) Curve fitting parameters are shown in the table.
doi:10.1371/journal.pgen.1006316.g002
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MBNL1 promoted skipping of an exon within the CLASP1 gene, but this event is a different
exon; the YGCY motifs for the previously reported event are upstream [23].
Comparisons of dose-responses for each event revealed differences in the manner of regula-
tion of each exon by MBNL1 (Fig 2). Exons inMBNL2,MBNL1, and ATP2A1 required less
MBNL1 protein than the other four events, yet NFIX required approximately three times more
MBNL1 protein thanMBNL2. Estimated EC50 values partially correlated to previously
reported affinity measurements of MBNL1 protein bound to minimal RNAs. For example,
exons with lower EC50s (ATP2A1, MBNL1, andMBNL2) tended to have stronger binding
(KDs of 15 nM, 11 nM, and 5.8 nM, respectively [10]); exons with higher EC50s (INSR,NFIX)
tended to have weaker binding (KDs of 120 nM and 55 nM, respectively) [10], [11]). Absolute
values of slopes ranged from 1.0–6.0, with values from 1–1.8 for FN1, INSR,NFIX,CLASP1
and ATP2A1, suggesting lack of apparent cooperativity. Interestingly, the autoregulated
MBNL1 andMBNL2 exons exhibited steeper slopes than all other events analyzed.We did not
observe a clear relationship between the number and location of YGCYs (S2 Fig) relative to
EC50 or slope values.
Binding site composition and organization mediate the dose-response
behavior of MBNL1 exon 5
The relationship betweenMBNL binding site organization and dose-response behavior is likely
complex and depends on multiple factors, including trans-factor environment and organiza-
tion of other cis-elements. However, by studying the splicing behavior of sequence variants of a
single event, we could limit the impact of these variables.We mutated cis-elements in the
intron upstream ofMBNL1 exon 5 to evaluate how putative MBNL binding sites affect dose-
response behavior (Fig 3A). This event contains clusters of YGCYs within an intronic splicing
silencer (ISS) that directly precedes regulated exon 5 [24,30] (Fig 3A). Previous work showed
MBNL1 binding to these YGCYs in mouse C2C12 myoblasts [29] (Fig 3A). The ISS is consid-
ered to be “ultraconserved”, with 100% sequence identity between human and mouse [31]. Pre-
viously, we showed that individual regions containing YGCYs were unnecessary to achieve
maximal splicing activity when eGFP-MBNL1 was overexpressed from a plasmid [24].
We asked whether altering the ultraconserved ISS YGCY organization altered MBNL1
dose-dependent splicing activity. Deletion of regions within the ISS (del1-5) altered YGCY
organization and spacing of splicing signals, including a distant branch-site and the 3’ splice
site (Fig 3A). Dox was titrated to induceMBNL1 expression, the del mutant pre-mRNA splic-
ing reporters were transiently transfected, and the percentage of spliced transcripts including
exon 5, or C, was quantified and fit to curves (Fig 3 and Table 1). Maximum C values were
similar to WT for all del mutants (CUG condition, Fig 3), indicating that the mutations did not
affect baseline levels of splicing. Minimum C values, or those at the highest MBNL1 dose, were
similar to WT for all deletionmutants except del 3, similar to previous observations using high
MBNL1 concentrations [24]. However, the shapes of the dose-dependent curveswere distinct
across the MBNL1 concentration range. The central deletionmutant, del3, had the largest
effect on the dose-response. This 18 nucleotide deletion resulted in removal of a single YGCY
in the center of the ISS, and led to both a shallower slope and a greater EC50 relative to WT. To
rule out additional explanations for why del3 exhibited a distinct dose-response, another mini-
gene reporter, 3M, was created in which the YGCY (UGCGCU)motif within the del3 region
was mutated to a sequence that MBNL does not bind, YCCY (UCCCCU) [32]. The dose-
response for 3M was similar to that of del3.
In contrast, del4, a deletionmutant lacking the YGCY 3' of del3, exhibited no significant
changes in dose-dependencyparameters. Another mutant, 4M, in which the del4 YGCY was
Dose-Dependent Alternative Splicing by MBNL1
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Fig 3. The composition of MBNL1 binding sites mediates dose-dependency of MBNL1 exon 5. (A) Mini-gene reporter sequence (exons 3-4-5
and intervening introns) of MBNL1 pre-mRNA showing the 3’ region of the intronic, ultraconserved sequence between exon 4 and the regulated, or
alternative, exon 5. YGCYs are indicated by colored boxes. The previously mapped distant branch point adenosine is indicated with an A [24].
Asterisks indicate C-T mutations from C2C12 cells (CLIP data, [29] (B-G) Mini-gene reporter dose-response curves were plotted (Ψ verses the log
([HA-MBNL1]), determined by western blot) for (B) del1 (C) del2 (D) del3 (E) del4 (F) del5 (G) 3M in triplicate. The WT (blue) dose-response curve
is included with each deletion mutant (red) for comparison. Quantification of the upper band (exons 4-5-6) and lower band (exons 4–6) were used to
determineΨ. A transiently transfected HA-MBNL1 plasmid was used to achieve the highest MBNL1 dose in this experiment and CTG960 transient
transfection was used to achieve the lowest levels of functional MBNL proteins through sequestration. Representative splicing gels are shown.
doi:10.1371/journal.pgen.1006316.g003
Dose-Dependent Alternative Splicing by MBNL1
PLOS Genetics | DOI:10.1371/journal.pgen.1006316 September 28, 2016 7 / 24
mutated, also exhibited dose-dependent behavior similar to that of WT (S3A Fig). These results
indicate that the cis-element organization of this region, in particular the sequence around the
central YGCY, may mediate specific dose-response characteristics.Most alterations to binding
motifs in this sequence space led to changes in dose-dependent behavior, including reduced
slope and increased EC50, potentially through reducing cooperativity or changing RNA
structure.
MBNL concentration can be inferred usingΨ from multiple splicing
events
In the HEK293 system, we observed that C of each splicing event exhibits a characteristic sig-
moid shape with respect to MBNL1 concentration. This well-controlled system allowed us to
derive these relationships, and directly measure functionalMBNL1 levels by Western blot.
However, a major goal in the DM field is to estimate the functional, non-sequestered concen-
tration of MBNL in tissue of DM patients. This metric is impossible to obtain from tissue using
current technologies, as free versus sequestered pools of MBNL are dynamic. However, the
dose-dependent curveswe characterized suggested that C could be used to infer the concentra-
tion of functionalMBNL in cells. While we observed that cis-element organization plays an
important role in dictating the shape of each dose-response curve, the trans-factor environ-
ment also likely plays a role, and therefore dose curve parameters will vary across tissues.
First, we assessed whether it was possible to infer MBNL concentration, given a set of C val-
ues measured across a range of MBNL doses.We framed the task of estimating [MBNL] and
all sigmoid curve parameters, Cmin, Cmax, EC50, and slope, as a Bayesian estimation problem.
Since we can compute the likelihoodof observingC for all seven splicing events from
HEK293, given any set of values for [MBNL], Cmin, Cmax, EC50, and slope for each splicing
event, Bayes’ Rule allows us to invert the problem to obtain the posterior probability distribu-
tion of each of those parameters, including the underlyingMBNL concentration. Indeed, when
estimated using this approach, inferred [MBNL] correlated extremely well (R2 = 0.993) with
measuredMBNL levels relative to GAPDH, as assessed by Western blot (Fig 4A). Interestingly,
a computationally simpler approach using the average splicing dysregulation across all splicing
reporters, mean Δ C, also correlates extremely well with MBNL levels as assessed by Western
blot (R2 = 0.994, Fig 4B).
Estimation of functional MBNL concentration in DM1 tibialis biopsies
After using the dose-dependent relationship of C to [MBNL] in the HEK293 system to develop
a method to estimate [MBNL] using C alone, we sought to apply this approach to measuring
Table 1. Curve fitting parameters of MBNL1 exon 5 deletion mutant mini-genes. Parameters for EC50, slope, and R2 for the MBNL1 deletion mutants
were derived from curve fitting using a four-parameter dose-response curve.
mbnl1 EC50 (rel MBNL1) slope R2 min max
construct [95% CI]
WT 0.19 [0.14 – 0.26] -1.8 ± 0.28 0.9244 0.41 ± 0.018 0.98 ± 0.036
del1 0.48 [0.21 – 1.1] -0.60 ± 0.14 0.9167 0.38 ± 0.047 1.0 ± 0.065
del2 1.2 [0.04 – 2.8] -0.33 ± 0.26 0.8163 0.26 ± 0.32 1.1 ± 0.25
del3 1.6 [0.59 – 4.1] -0.56 ± 0.18 0.8500 0.54 ± 0.058 1.0 ± 0.046
del4 0.15 [0.10 – 0.22] -2.0 ± 0.67 0.8075 0.39 ± 0.026 0.96 ± 0.058
del5 0.29 [0.07 – 1.0] -0.67 ± 0.27 0.7983 0.49 ± 0.049 0.95 ± 0.066
3M 1.7 [0.54 – 5.3] -0.45 ± 0.16 0.9126 0.32 ± 0.10 1.0 ± 0.081
doi:10.1371/journal.pgen.1006316.t001
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Fig 4. Inferring MBNL concentration usingΨ in HEK293 and DM1 tibialis anterior. (A) [MBNL] inferred using Bayesian estimation highly correlates to
measurements of MBNL protein relative to GAPDH as assessed by Western blot in the HEK293 system. (B) Total splicing dysregulation, mean ΔΨ,
correlates strongly with measurements of MBNL protein relative to GAPDH in HEK293. (C) Bayesian estimation was used to infer [MBNL] in 55 tibialis
anterior biopsies; [MBNL]inferred values also strongly correlate with total splicing dysregulation, mean ΔΨ, in tibialis. Non-DM1 individuals are shown in
green. (D) Heat map of normalizedΨ (each event was set from 0 to 1, to aid visualization) for forty-six splicing events in forty-four DM1 patients and eleven
healthy controls. Similar, non-normalized data is shown in S4 Fig.Ψmin,Ψmax, EC50, and slope values were inferred simultaneously with [MBNL] using
Bayesian estimation (S3 Table). Samples are sorted by [MBNL]inferred across the horizontal axis, and splicing events are sorted by EC50 along the vertical
Dose-Dependent Alternative Splicing by MBNL1
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functionalMBNL concentration in the tibialis anterior skeletal muscle, a tissue preferentially
affected in DM1. Cognizant that the behavior of each dosing curvewould differ in tibialis as
compared to HEK293, we separately characterized dosing curves in tibialis, by analyzing RNA-
seq data from 44 DM1 patients (including 5 patients with proto-mutations, or<100 CTG
repeats as assessed by peripheral blood) and 11 healthy controls (sample cohort described in
[17]). MISO was used to derive transcriptome-wide estimates for C values of alternative cas-
sette exons [33]; we focused on 46 cassette exon splicing events exhibiting significant differen-
tial splicing regulation in at least 25% of DM1 samples (MISO Bayes Factor  5 when
comparing DM1 to non-DM1, and |Δψ|> 0.2) (S1 and S2 Tables). MISO C estimates were in
agreement with values obtained from RT-PCR [17].
While in the context of DM1 many factors potentially influenceΔC, the panel of events
identified in this study is consistent with a predominant contribution fromMBNL sequestra-
tion. YGCY motifs were enriched upstream of the regulated exon for events that are more
included in patients (p = 0.001) while YGCY motifs were enriched downstream of the regulated
exon for events that are more excluded in the patients (p = 0.006), consistent with previously
describedMBNL1 binding site maps and observations connectingMBNL1 putative motif loca-
tion and association with either inclusion or skipping of the alternative exon [10,28,29]. Addi-
tionally, previous studies indicate that MBNL depletion accounts for the majority of splicing
events observed in the HSALRmouse model of DM1 [28].
Six out of seven splicing events studied in the HEK293 system were also observed to be dys-
regulated in DM1 tissue; FN1was excluded because it lacked sufficient RNA-seq coverage to
accurately infer splicing. To characterize dosing curves in tibialis, we applied our Bayesian
inference framework, which infers Cmin, Cmax, EC50, and slope for each splicing event in
tibialis, as well as functionalMBNL concentrations for each individual. As expected due to
differences in trans-factor environment and expression level, among other variables, dose-
dependent curveswere observed to be similar, but not identical betweenHEK293 and tibialis
anterior (S5 Fig). Interestingly, while curve shapes were similar across both cell types, those in
tibialis generally exhibited a broader dynamic range in C, as well as steeper slopes, suggesting
that the trans-factor differences in tibialis result in an enhanced dependency of C on MBNL
concentration.
Similarly to the HEK293 system, we observed that the intracellular concentration of func-
tional MBNL ([MBNL]inferred) correlated well with mean splicing dysregulation (Fig 4C); this is
simply a reflection of the fact that the Bayesian Inference approach aggregates C frommultiple
events to generate its estimates. Ordering individuals by relative [MBNL]inferred resulted in
non-DM1 individuals grouping together with individuals carryingDM1 proto-mutations, con-
sistent with limitedMBNL sequestration occurring in this subset of DM1 patients (Fig 4D).
Some events showed dysregulation in almost all patients (86% of patients exhibit dysregulation
for INSR), and others showing dysregulation in a smaller subset of patients (48% of patients
exhibit dysregulation for ATP2A1), consistent with some events exhibiting higher EC50 values
than others (Fig 4D and S1 Table). C for all samples and all splicing events, along with esti-
mated sigmoid curves, are shown in S6 Fig. Although reported repeat lengths [17,34–36] for a
subset of fifteen TA muscle samples did not correlate to [MBNL]inferred values (R2 = 0.0841)
(S7A Fig) or muscle weakness (17), it is well established that repeat lengths can differ from cell
to cell of the same individual, and that long repeats are extremely difficult to size accurately.
axis. The |slope| for each event is indicated on the right-hand vertical axis. White boxes with slashes denote samples with insufficient read coverage to infer
Ψ. Events studied in HEK293 are marked with an asterisk.
doi:10.1371/journal.pgen.1006316.g004
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However, ankle dorsiflexion (ADF) strength measurements were moderately correlated with
[MBNL]inferred (R2 = 0.358) (S7B Fig).
Accurate inference of MBNL concentration is splicing event and disease
severity dependent
We sought to assess the suitability of each splicing event as a potential biomarker for levels of
functional, non-sequesteredMBNL, a key metric likely correlated to clinical outcomes in DM1.
To simulate a hypothetical future clinical trial scenario in which we have estimated Cmin,
Cmax, EC50, and slope using one cohort of DM1 patients, and would like to estimate [MBNL]
for a new cohort of patients, we divided our samples into two groups to perform traditional
cross-validation.We used 70% of the individuals to estimate Cmin, Cmax, EC50, and slope for
every splicing event (training); these trained parameters could be used to plot sigmoid curves
for each event (NFIX and CLASP1 shown in Fig 5A). We then assessed how well we could pre-
dict [MBNL] for the remaining 30% of samples (testing), by framing the question as another
Bayesian inference problem. Here, we obtained the posterior probability distribution for
[MBNL] by computing p([MBNL] | C) p(C | [MBNL]).
We then used the trained parameters to estimate a posterior probability distribution for
[MBNL], framing the question as another Bayesian inference problem. Posterior distributions
for [MBNL], obtained using measurements of C for NFIX or CLASP1 are displayed in blue,
green, and orange shading, for C values observed in 3 distinct biopsy samples (Fig 5A, right
panel). The “gold standard” estimates for [MBNL], previously calculated using 100% of the
data, are displayed in blue, green and orange vertical lines. Apparent from these estimates is
that the precision with which [MBNL] can be predicted is dependent on the shape of the sig-
moid curve. For example, a precise value for [MBNL] in a severely affected individual (based
on ADF measurements) is more difficult to obtain usingNFIX as compared to CLASP1,
becauseNFIX offers little discriminatory power between 0 and 0.5 [MBNL] units. In contrast,
the predictive power of NFIX is slightly better than that of CLASP1 for mildly affected patients,
as the sigmoid curve for NFIX changes more steeply than CLASP1 at the high end of [MBNL].
CLASP1 is an excellent predictor in the moderate range (green); the posterior probability esti-
mate at the “true” [MBNL] value is close to 7 (Fig 5A).
These examples illustrate the principle that some splicing events are better than others for pre-
dicting [MBNL], and that their predictive power is dependent on disease severity. To quantitate
the performance of each splicing event to estimate [MBNL], we calculated the mean predictive
power of each splicing event to estimate “true” [MBNL] across 120 randomly sampled 70%/30%
training/testing cohort divisions, where predictive power is defined as the posterior probability
estimate at “true” [MBNL].We calculated the mean predictive power for each event across sev-
eral patient subgroups–severe ([MBNL]< 0.33), moderate (0.33< [MBNL]< 0.66), and mild
([MBNL]> 0.66) DM1, as well as across the entire patient cohort. Splicing events best suited to
predict [MBNL] in mild DM1 are distinct from those best suited to predict moderate or severe
DM1 (Fig 5B). Interestingly, splicing events best suited to predict [MBNL] in moderate DM1 are
also those best suited to predict [MBNL] across the entire spectrum(CLASP1, PDLIM3.2,CAC-
NA2D1). Analyses of sigmoid curves for the best performers (S4 Fig) indicated that the best pre-
dictors exhibit non-zero slopes within the range of [MBNL] being predicted.
Measurement of therapeutic rescue requires proper biomarker selection,
and usage of multiple biomarkers improves measurement accuracy
It is well established that the goal of many therapeutic efforts for DM is to increase the free,
functional concentration of MBNL in cells and tissues; therefore, it is critical to be able to
Dose-Dependent Alternative Splicing by MBNL1
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Fig 5. Splicing events as biomarkers to measure functional MBNL concentration in DM1 muscle and response to therapeutics. (A)Ψmin,Ψmax,
EC50, and slope, as well as [MBNL], were estimated for each splicing event and each sample, using 70% of the tibialis biopsies using a Bayesian inference
framework. Sigmoid curves with 95% confidence intervals for NFIX and CLASP1, as estimated from 70% of the data, are shown, along with theΨ values
used to derive the curves (black points). Posterior distributions for [MBNL] were derived for 30% of the data (red points), and plotted for 3 specific samples
(blue, green, and orange points). These distributions are also plotted on the right, along with the “gold standard” [MBNL] as estimated using 100% of the
data (blue, green, and orange vertical lines). (B) The mean predictive power of each splicing event to predict “true” [MBNL] was calculated across 120
random subsets of training and test sets, where 70% of samples were used for training, and 30% for testing. Predictive power was defined as the posterior
Dose-Dependent Alternative Splicing by MBNL1
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measure changes to this metric before and after a clinical study/trial. A hypothetical change in
[MBNL] may or may not lead to changes in C for any given splicing event; the change in C is
dependent on the shape of the sigmoid curve, as well as the starting point and ending point
within the curve (Fig 5C). For example, a positive change of 0.4 [MBNL] units for a severely
affectedDM1 patient will result in changes to C for CLASP1 but not NFIX (Fig 5C, left panels,
purple points and arrows). Posterior estimates for pre- and post-treatment [MBNL] using sig-
moid curve parameters are poorly separated for NFIX, yet well separated for CLASP1 (Fig 5C,
purple shading). In contrast, a positive change of 0.3 [MBNL] units for a moderately affected
DM1 patient results in well separated pre- and post-treatment [MBNL] estimates for both
NFIX and CLASP1 (Fig 5C, brown data points).
Thus far, our analysis has made use of only one biomarker at a time to estimate [MBNL].We
tested the ability to improve estimates by incorporatingmultiple biomarkers; we essentially com-
puted the joint probability distribution of [MBNL] as estimated by each separate biomarker. We
identified biomarker combinations that wouldmaximize predictive power across all disease
severities, again using 70%/30% cross-validation training/test sets. For each cross-validation trial,
we first identified the single best biomarker with maximum predictive value for [MBNL]; we
then identified the next best biomarker that minimized errors in concert with the best biomarker,
then the third in concert with the first two, and so on.We performed this analysis across all 120
cross-validation trials, and recorded the biomarker sets with highest mean predictive power
across all trials. Shown in Fig 5D are posterior estimates of [MBNL] for a severely affected biopsy
and moderately affected biopsy, using the best 1, 2, 5, or 10 biomarkers (Fig 5D). As expected,
the probability distribution becomes sharper and more centered on the “true” [MBNL]. Adding
more biomarkers can improve the estimation up to ~30 markers (Fig 5E), after which further
marker addition decreases performance. The decrease in performance is likely due to use of C
values from splicing events whose inclusion is not as tightly linked to [MBNL].
Discussion
Splicing events exhibit distinct responses to MBNL concentration
We studied the behavior of 7 splicing targets in a cell line we developed, in whichMBNL1
expression could be titrated across a 20-fold dynamic range (Fig 6A). Each splicing event
exhibited a unique, sigmoidal dose-response curve, with distinct EC50 and slope parameters.
The steepness, or slope, of C relative to [MBNL1] varied across splicing events, likely due to
cooperative binding of MBNL1 and/or other proteins to pre-mRNA. MBNL1 is known to regu-
late the splicing of other splicing factors such as PTB1 and hnRNPA1 and the stability of tran-
scripts encoding splicing factors [29], so it is possible that secondary effects play a role in
producing the observed sigmoid curves.
One might hypothesize that multiple binding sites are more likely to function in a coopera-
tive fashion and that high affinity binding would lead to a lower EC50, but we did not observe a
probability estimate at “true” [MBNL] assessed using all the data. The mean predictive power was computed separately across three patient subgroups–
severe ([MBNL] < 0.33), moderate (0.33 < [MBNL] < 0.66), and mild ([MBNL] > 0.66) DM1, as well as across the entire patient cohort. Mean predictive
power for each patient subgroup was plotted versus mean predictive power across the entire cohort, or all patients; splicing events that perform better in
specific subgroups relative to the entire cohort are labeled. (C) The ability to estimate changes in [MBNL] depends on the splicing event used to infer
[MBNL], as well as the disease severity at which treatment is initiated. Hypothetical changes in [MBNL] of +0.4 and +0.3 during a therapeutic trial are
illustrated as purple and brown filled and outlined points, respectively in left panels. The posterior probability estimates of [MBNL] are illustrated in right
panels. (D) A greater number of biomarkers can improve predictive power of estimates of [MBNL]. The posterior probability distribution for [MBNL] is shown
when using 1, 2, 5, or 10 biomarkers for severely affected tibialis (top panel) or moderately affected tibialis (bottom panel). The value of [MBNL] obtained
when using 100% of samples is shown as a dotted line; the posterior probability at this value of [MBNL] increases as the number of biomarkers increases.
(E) Mean predictive power increases when using more biomarkers, up to a point. The best possible combination of biomarkers was chosen for each cross-
validation trial, and predictive power was averaged across 120 cross-validation trials.
doi:10.1371/journal.pgen.1006316.g005
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simple relationship between the number and location of MBNL binding sites and EC50 or slope.
The location of MBNL bound cis-elements is similar when comparingMBNL1 exon 5 and
MBNL2 exon 5, and they exhibited similar dose-dependent responses (Fig 2 and S2 Fig). The rela-
tionship betweenMBNL binding site number, location and affinity almost certainly play an
important role in determiningMBNL1 dose-responses, but it is also likely that other splicing fac-
tors, RNA structure and gene expression levels canmodulate these curves.Other factors that regu-
late splicing in DM1 TA muscle, including CELF1 proteins, will also affect the curve parameters.
CELF1 antagonistically regulates someMBNL regulated events including INSR [37–39].
The relationship between MBNL binding site organization and dose-
dependent behavior
We studied the role of specific binding sites upstream ofMBNL1 exon 5 in mediating its
MBNL dependent dose-response (Fig 3). Inclusion ofMBNL exon 5 controls localization of the
Fig 6. Summary. (A) In our HEK293 inducible model, free [MBNL1] can be titrated by administration of doxycycline (top panel).
In myotonic dystrophy, free [MBNL] proteins are titrated by sequestration to toxic CUG RNA (bottom panel). (B) Deletion of
YGCY sites within the ultraconserved intron upstream of MBNL1 exon 5 influences dose-dependent curve parameters EC50,
slope, both, or neither. (C) Biomarkers are most informative in the regions with a non-zero slope (red parts of curve). The best
biomarkers also tend to have a broad dynamic range (Ψmax-Ψmin).
doi:10.1371/journal.pgen.1006316.g006
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protein, and appears to be tightly regulated by MBNL and other proteins [29,40,41]. This
region is an “ultra-conserved region” [31], and previous work has shown that in mouse myo-
blasts, MBNL1 protein interacts with the region mutated in these experiments [29]. Some
YGCY motifs were dispensable for splicing whenMBNL1 was high [24], but at low concentra-
tions, somemotifs were more critical than others.
The site that most dramatically altered dose-dependent behavior was a single, central
YGCY. Affinity and cooperativity parameters were reduced for the del2/3 regions while del1/5
only had reduced cooperativity (Fig 6B). MBNL1 may bind to central sites first causing the sur-
rounding sites to becomemore accessible, consistent with the footprinting data of this RNA
(Fig 6B and S3B Fig). Structure probing indicated that the central YGCYs were single stranded
in vitro ([24] summarized in S3B Fig) and that the RNA was generally not structured.Notably,
previous studies indicate that MBNL1 binds to regions of short single stranded RNAs through
theWatson-Crick face of short unstructuredRNAs [10,32,42]. Alternatively, differences in
structure between the del mutants may have contributed to the observeddifferences in EC50
and slopes observed (S3B Fig) (mfold server, [43]). For example, the open structures for WT
and del4 may facilitate a cooperative dose-response and increased sensitivity to MBNL1 con-
centrations, while the alternative structuremay be a weaker substrate for MBNL1 (S3B Fig).
Indeed, recent data suggests a model where MBNL1 interacts with the toxic CUG RNA when it
is destabilized by U-Umismatches, allowingMBNL1 to access locally unfolded GC sites
[44,45].
Alternative splicing event biomarkers
A key goal in the DM field is to accurately assess the remaining functional levels of MBNL pro-
teins in human tissue. Using the cell-based system, we developed and validated a computa-
tional method to estimate MBNL1 concentration, as well as splicing curve parameters, using C
alone. The strong correlation between estimated and measuredMBNL1 protein levels in the
cell-based systemmotivated us to take a similar approach in human tibialis biopsies from DM1
affected and non-affected individuals, where freeMBNL proteins vary between individuals (Fig
6A). We estimated tibialis-specific splicing curve parameters, which differed from those
observed in the cell-based system, and also estimated the levels of functionalMBNL protein
remaining in tissue. As MBNL proteins regulate the splicing of many pre-mRNA substrates, a
major unresolved question is which splicing events are most informative about disease status,
and which splicing events in combination are best suited to measure therapeutic rescue in a
clinical trial. It is well established that the remaining functional level of MBNL protein in tissue
is informative about disease status, and here, we demonstrate that we can estimate this value
using C alone, provided we first build a model using C from a number of splicing events across
a spectrumof disease severities.
We showed that the range of [MBNL] across which C varies is different across events, and
that this characteristic determines which subset of patients (mild, moderate or severe) for
which that biomarker exhibits the greatest predictive power (Fig 6C). This has implications for
being able to accurately place patient samples along the continuum of disease severities
observed in DM, and for being able to accurately measure the extent of therapeutic rescue in a
clinical trial. Furthermore, splicing biomarkers whoseC values are invariant across a particular
[MBNL] range do not provide as much information as biomarkers whoseC values change dra-
matically across that same range. Finally, we showed that using multiple biomarkers in combi-
nation to predict [MBNL] holds more predictive power than using single biomarkers alone.
The best biomarkers significantly overlap with those previously described [17]; we found the
top set of five biomarkers for tibialis to be CLASP1, PDLIM3.2, CACNA2D1,MAPT.1 and
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CACNA1S (Fig 5D and S3 Table). Interestingly, CLASP1 is a novel event identified in our
RNA-seq analysis; it is the top biomarker among all tested, and exhibits a broad range of splic-
ing regulation across [MBNL] in both the cell based system and in tibialis. (Fig 2 and S6 Fig).
Dose-dependent behavior differs in different cellular contexts
The relationship betweenMBNL1 levels and C was previously investigated in myoblasts and
mouse muscle [20]. C for five splicing targets was measured at five concentrations of MBNL1
in myoblasts, achieved by different doses of siRNA; C for similar events was measured at 0%,
50% and 100%MBNL1 level in mouse muscle, using normal, heterozygote, and homozygote
MBNL1 knockouts. The relationship of C to [MBNL1] was slightly different in myoblasts ver-
sus muscle, depending on the specific exon, suggesting that a complex mixture of cis- and
trans-factors mediates dose-dependent behavior, with differing stoichiometry in different cel-
lular contexts. Here, we have separately measuredCmin, Cmax, EC50, and slope values for each
splicing event in both HEK293 cells and human tibialis, and also observed that these parame-
ters differ betweenHEK293 cells and human tibialis. These observations suggest that proper
selection of splicing biomarkers for a given cell type requires characterization of biomarkers in
that tissue, or a basic understanding of how C is modulated by the interaction of multiple
trans-factors with pre-mRNA cis-elements.
Materials and Methods
HA-MBNL1 expression stable cell line production
The full lengthMBNL1 (isoform 41) with an N-terminal HA tag was cloned into the supplied
vector (pcDNA5) and transfected into the HEK293 T-REx FLP cell line (Life Technologies) to
create the inducible line following the manufacturer's protocol.
Western blotting
HEK cell pellets were lysed in (RIPA) buffer (50 mMTris, pH 7.4, 150 mMNaCl, 1% NP-40,
0.25% sodium deoxycholate, 0.1% SDS, 1 mM phenylmethylsul- fonyl fluoride [PMSF]) sup-
plemented with 1x protease inhibitor cocktail (SigmaFAST; Sigma) by light agitation for 20
min via vortex, and the concentration of protein was normalized using bicinchoninic acid
(BCA) reagent (Pierce) prior to resolution on 10% SDS-PAGE gels. MBNL1 proteins were
probed with antibody (MB1a (4A8)) [46] probed at 1:2000 and 1:15,000 goat anti-mouse sec-
ondary IRDye 800CW (Licor). GAPDH loading control was probed (1:1000) ((14C10) Rabbit
mAb #2118, Cell Signaling) followed by goat anti rabbit IRDye 680 RD (Licor). Fluorescence
was measured using a Licor Odyssey Fc instrument.
Splicing reporters and mini-gene mutagenesis
The wild typeMBNL1 mini-gene was made by amplifying regions of the MBNL1 gene contain-
ing 51 nucleotides from the 3'-end of intron 3, exon 4, intron 4, exon 5, intron 5, exon 6, and
33 nucleotides of the 5' -end of intron 6 from HeLa genomic DNA using PCR primers with
unique restriction sites.Mbnl1 deletion constructs are describedpreviously [24]. Site directed
mutagenesis of theWT and del mutants constructs was performed to create the mutations 3M
and 4M using the Phusion Site-DirectedMutagenesis Kit following the manufacturer’s proto-
col (Thermo Scientific). The following primers were used for mutagenesis: 3M: Forward: 5’-
GTTTATGTTAATCCCCTTGAACCCCAC -3’, Reverse: 5’-AGCAAGCAGAGGTGCATC
ATG-3’, 4M: Forward: 5’- CTGGCCCATTCCCATCATGT -3’ Reverse: 5'-TGGGGTTCAAGC
GCATTAACAT-3'.
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Cell culture and transfection
HEK293 cells with inducible MBNL1 were routinely cultured as a monolayer in Dulbecco’s
modifiedEagle’s medium (DMEM)-GlutaMax (Invitrogen) supplemented with 10% fetal
bovine serum (Gibco) at 37°C under 5% CO2. Cells were plated in twenty-four-well plates
at a density of 1.5 x 105 cells/well. Fresh doxycycline (Sigma) or tetracycline (Sigma) was pre-
pared at 1 mg/ml, diluted, and added to the cells at the appropriate concentrations. A pool of
three siRNA duplexes (CACUGGAAGUAUGUAGAGAdTdT, GGACAAAUGUGCUUG
GUUUUUU, and GAGAGAAACCUGUAUAAUAUU) were transfected into the cells
24 hours prior to harvesting cells using TransIT-siQUEST transfection reagent as per the
manufacturer's protocol. Prior to transfection, cells were plated in twenty-four-well plates
at a density of 1.5 x 105 cells/well. Cells were transfected 24 h later at approximately 80%
confluence. Plasmid (500 ng/well) was transfected into each well with 1.5 ul of TransiT 293
(Mirus) following the manufacturer’s protocol. 250 ng of either empty vector (pcDNA3.1+) or
DMPK-CTG960 was co-transfected into a single well with 250 ng of mini-gene reporter for all
splicing assays. For DMPK-CUG960 and HA-MBNL (pcDNA3.1+) each reporter was reduced
so that the total DNA transfected remained constant and the ratio of DNA to transfection
reagent remained constant. Fresh doxycycline (Sigma) or tetracycline (Sigma) was prepared
at 1 mg/ml, diluted, and added to the cells at the appropriate concentrations four hours post
transfection. The DMPK-CUG960 plasmid was obtained from the laboratory of Thomas
Cooper.
Splicing activity assays
Cells were lysed in the plate and RNA isolated using an RNeasy kit (Qiagen) twenty hours after
induction. Isolated RNA (200 ng) was reverse transcribed using Superscript II (Invitrogen),
according to the manufacturer’s protocol. The RNA for all endogenous splicing event condi-
tions were internally controlled by recovering RNA from the same plated well of cells. Endoge-
nous genes were reverse transcribed using random hexamers except for MBNL1, which a gene
specific primer was designed to anneal to endogenous transcripts but not the HA-MBNL1
transgene transcripts:
5’-CTGAGGAACTTTTGTGTGTGTTGCTTGACG-3’. All reverse transcription reactions
were subjected to PCR amplification in a 20 ul reactionmixture using flanking exon-specific
primers. The number of amplification cycles was determined to be within the linear range for
all primers used. Endogenous gene PCR primers (hg19 coordinates are the same as in S2




R: 5’-GCTGGGACTGTGAAACCACTTTAGC-3’, MBNL1:F 5-AGGGAGATGCTCTCGGGAAAAGTG-
3’, R 5’-GTTGGCTAGAGCCTGTTGGTATTGGAAAATAC-3’,MBNL2 (from [17]):F 5’-
ACAAGTGACAACACCGTAACCG-3’, R 5’-TTTGGTAAAGGATGAAGAGCACC-3’,NFIX: F 5’-
GATGGAGAGCCCTGTTGATGACG-3’ R 5’-GTGGTGGTGGTAGCGGATGGTC-3’and FN1 (exon
hg19 coordinateschr2:216257654–216257926)F 5'- AGAATTACCACAACCCCTACAAA
CGG -3' R 5'- TGCATTGTCTGAAGGAGAAATTGACAACTC-3'.
PCR products were resolved by gel electrophoresis on 1.5-mm, 6% native polyacrylamide
(19:1) gels run at 300 V for 90 min. Splice products were visualized and quantified using SYBR
green I nucleic acid stain (Invitrogen) in combination with an AlphaImager HP system (Alpha
Innotech). All reported values were obtained from at least three independent splicing experi-
ments. All experiments with MBNL1 pre-mRNA mini-genemutations included a WT internal
control.
Dose-Dependent Alternative Splicing by MBNL1
PLOS Genetics | DOI:10.1371/journal.pgen.1006316 September 28, 2016 17 / 24
RNAseq
Muscle biopsies, repeat length estimation, and patient strength measurements were conducted
as described in Nakamori et al [17] and [47]. 1 ug of total RNA was prepared for Illumina
strand-specificRNA-seq using standard methods. In brief, rRNA was removed using the Ribo-
zero beads (Epibio), and remaining RNA was fragmented using fragmentation buffer (Ambion
#AM8740). RNA was precipitated and converted to cDNA using Superscript III, random prim-
ers, and dUTP, and 2nd strand cDNA using DNA polymerase I and RNase H. Ends were
repaired, adenylated, and ligated to Illumina paired end adapters. Ligated fragments were puri-
fied by agarose gel electrophoresis (~200 bp band was excised), treated with USER enzyme,
and subjected to 14–18 cycles of PCR. A second gel was run to purify product away from prim-
ers. Libraries were sequenced in pooled sets of 4 or 6 samples on the Illumina Hiseq, using 2 x
57 bp sequencing runs.
Identification of mis-spliced exons in DM1 patient samples
Illumina RNA-sequencing reads from the tibialis anterior muscle biopsies (44 DM1 and 11
unaffected control) were aligned against the hg19 human reference genome with GSNAP and
allowing for novel splicing [48] (http://research-pub.gene.com/gmap/). GSNAP was run with
the following options set:–s [splice sites map file]–N 1 –A sam–o FR—pairexpect 300—pairdev
100. A splice sites map file was generated from the hg19 gene models (GrCh37 release 75). Iso-
form abundances were estimated and each of the 44 DM1 samples was compared to each of
the 11 control samples usingMISO [33]. A custom set of hg19 alternative event annotations
were generated from the Refseq, Ensembl, and UCSC gene models using custom scripts. For
this analysis we focused only on the differential inclusion and exclusion of “cassette” exons
between the DM1 and control samples. The comparison data was filtered based on the criteria
describedbelow to identify a high confidence set of misregulated alternative exons events.
Filtering criteria:
1.  70% of control and DM1 samples have sufficient coverage over the event.
a. ∑ inclusion and exclusion reads 20
2. jDcj  0:20
3.  25% of DM1 patients showed evidence for differential splicing compared to controls.
a. median Bayes factor 5
Curve fitting (Figs 1–3)
For data in Figs 1–3, splicing activity curveswere fitted using Graphpad Prism software using
non-linear curve fitting (log(agonist) vs. response—Variable slope (four parameters)). The min
and max were restricted to fall between 0 and 1, respectively.
YCGY motif enrichment near differentially regulated exons
A student's t-test was used to compare the presence of 4-mer motifs that bind MBNL proteins
(identified previously [10]), using a 20 bp sliding window within the 400 bp region upstream of
cassette exons that are more excluded in controls, with respect to patients, to the same region
of an identical number of randomly sampled exons (average sampled using 1000 iterations). A
similar comparison was performedwith motifs located 400 bp downstream of cassette exons
that are more included in controls, with respect to patients.
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Bayesian inference to estimate curve parameters and [MBNL]
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the observed inclusion level of an exon across multiple doses or samples, and ϕ describesCmin,
Cmax, log(EC50), slope, [MBNL], and a parameter σ. We assume that observedC values are
drawn from a normal distribution centered around the modeledC value, with standard devia-
tion σ. Priors for each estimated parameter were as follows: Cmin ~ Uniform(0, 1), Cmax ~ Uni-
form(0, 1), log(EC50) ~ Normal(μ = 0.5, σ = 1), slope ~ Normal(μ = 0, σ = 1), [MBNL] ~
Uniform(0, 1), σ ~ Uniform(0, 1). The python package PyMC3 was used to implement Bayes-
ian inference [49]. MCMC sampling was performed using the NUTS sampler and 1000 itera-
tions. This approach was used to infer [MBNL] for all panels in Fig 4, separately for HEK293
data and tibialis data. Estimated parameters were used to generate curves in S4 Fig.
Cross-validation analysis, generating posterior estimates of [MBNL],
and biomarker analysis
We assessed the ability of each splicing event to predict [MBNL] by performing a cross-valida-
tion analysis. We divided the tibialis samples into 2 groups, comprising 70% and 30% of sam-
ples. Cmin, Cmax, log(EC50), slope, [MBNL], and σ were estimated using 70% of the samples,
as described above. Then, for each splicing event and each sample in the remaining 30% of
samples, we calculated a posterior distribution for [MBNL].We essentially performedBayesian
inference again, framing the problem as computing the probability of [MBNL] across all possi-
ble values of [MBNL]. That is, we computed p([MBNL]|φ,ω)/ p(φ|[MBNL],ω)  p([MBNL],
ω). Here, ω describesCmin, Cmax, log(EC50), slope and σ, a parameter describing the standard
deviation of the normal distribution from which observedC values are drawn from the mod-
eled C value (similar to above). In this case, however, σ is directly computed from the training
data, so that events with observedC values that closely match predictedC are more highly
favored as biomarkers. Fig 5A shows example posterior distributions of [MBNL] for points
highlighted in blue, green, and orange. We defined “predictive power” as the value of the poste-
rior distribution of [MBNL] where [MBNL] equals that estimated when using 100% of the
data. To compute the mean “predictive” power for mild, moderate, or severely affected sam-
ples, we averaged predictive power for samples with [MBNL]> 0.66,0.33< [MBNL]< 0.66,
and [MBNL]< 0.33 (Fig 5B). To compute predictive power when using multiple splicing
events as biomarkers, rather than take an exhaustive approach, which would require testing
upwards of billions of combinations of splicing biomarkers (for example, to sample 46 choose
10 is ~4 billion), we took a recursive addition approach, where we identified the best bio-
marker, then identified a second biomarker yielding the best performance in concert with the
best biomarker, then a third biomarker yielding the best performance in concert with the first 2
biomarkers, and so on (the best biomarkers are shown in Fig 5D). Predictive power was com-
puted as the joint probability distribution of all posterior estimates of [MBNL] for chosen
biomarkers.
Schematic diagrams of splicing events
YGCY motifs were plotted to scale within the regulated exon, 200 nucleotides upstream of the
regulated exon and 200 nucleotides downstream of the regulated exon.
TPM calculations (S1 Fig)
Kallisto [50] was used to estimate transcripts per million using a kallisto transcriptome index
generated from the hg19 Refseq/Locuslinkcoding sequences (CDS) fasta data set. Paired-end
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FASTQ files were used for TPM quantification and the average fragment length of the elibary
was automatically esimated by Kallisto. Total TPM values were calculated by summing Refeq
TPM values across all corresponding Refseq IDs for a given geneID.
Supporting Information
S1 Fig. Relative transcript levels of MBNL paralogs.MBNL1/2/3 transcripts were estimated
using RNA seq from six HEK293 cell samples. Transcripts per kilobasemillion are reported.
(TIF)
S2 Fig. YGCY motifs of MBNL1 regulated events. 200 nucleotides upstream and downstream
of the regulated exon are depicted with YGCY motifs marked. Schematic element spacing is
drawn to scale.
(TIF)
S3 Fig. Additional mutation inMBNL1mini-gene reporter and predictedRNA structures
of wild type and mutant RNAs. (A) 4M has similar behavior to WT. Splicing of 4Mmutant
compared withWTMBNL1mini-gene reporter in triplicate. Experimental details are the same
as in Fig 3. Representative gel is shown. (B)MBNL1 intron 4 is generally unstructured. Intron 4
mapped with previously determined structural data [24]. Single stranded regions are marked
with a dashed line, nucleotides with increased cleavage in the presence of MBNL1 are marked
with an E, and MBNL1 protected nucleotides are marked with a P (C) Predicted secondary
structures obtained using the mfold server forMBNL1WT and mutant RNAs [43].
(TIF)
S4 Fig. C Estimates for forty-six splicing events fromDM1 and control tibialis muscle.
Heatmap of event C estimates (un-normalized) from DM1 and control RNA-seq tibialis sam-
ples. Samples are ordered from left to right by decreasing |ΔC| summed over all events.
(TIF)
S5 Fig. Events differ in their dose-responsesbetweenHEK293 and TA muscle. (A) C was
plotted against [MBNL1] as determined by western blot in HEK293 for NFIX (blue), ATP2A1
(purple), INSR (black),MBNL1 (red),MBNL2 (green), and CLASP1 (orange) (left panel) and
TA muscle C was plotted against inferred [MBNL] (right panel). The x-axes are log10 scale.
Individual points and error for each event is shown is Fig 2 and S6 Fig.
(TIF)
S6 Fig. Individual splicing curves in DM1 and control tibialis muscle.C estimates are plot-
ted against the inferredMBNL1 for each splicing event. Inferred dose-response curve are
shown.
(PDF)
S7 Fig. Strength of AnkleDorsiflexion (ADF) but not number of CTG repeats correlates
with average dysregulation. (A) CTG repeat length was not correlated with inferred [MBNL]
in the tibialis muscle samples (R2 = 0.0841). (B) The maximal isometric force of ankle dorsiflex-
ion (ADF), measurement (expressed as the percentage of strength that would be predicted in a
healthy person of same age, gender, and height) moderately correlates with inferred [MBNL]
(R2 = 0.358).
(TIF)
S8 Fig. YGCY motifs within eventsmisregulated in DM1 tibialis muscle. 200 nucleotides
upstream and downstream of the regulated exon are depicted with YGCY motifs marker.
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Schematic element spacing is drawn to scale.
(TIF)
S1 Table. Events misregulated in DM1 compared to unaffected control tibialis. Splicing
event coordinates fromMISO from hg19, gene symbol, mean C for control and DM1 samples,
standard deviation,mean ΔC, number of samples used to calculate the mean for control and
DM1, number of samples for each event with a Bayes Factor greater than 5, and % patients
with dysregulated splicing for each event (ΔC> 50%, normalized to the maximum ΔC for
each event) are shown in the table.
(XLSX)
S2 Table. C estimates for events perturbed in DM1 tibialis muscle compared to unaffected
controls. C estimates fromMISO for genes (indicated by gene symbol and hg19 coordinates)
are shown for all samples in this study. NA is used for samples that did not have sufficient cov-
erage to obtain an estimate for that splicing event.
(XLSX)
S3 Table. Curve-fitting parameters for events dysregulated in DM compared to unaffected
controls. Bayesian posteriormean estimates for parameters min C, max C, EC50, slope,
respective 5% and 95% confidence intervals, and σ are shown for each splicing event (event_-
parameters tab). Inferred [MBNL], 5% and 95% confidence intervals, and mean delta psi are
shown for each sample (MBNL_inferred tab). Biomarker predictive power for all events (Fig
5B) and optimal combinations for choosing one to forty-six biomarkers (Fig 5D) are shown
(single_biomarkers and biomarker_combinations tabs, respectively).
(XLSX)
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